ABG
DICE

Ally Bridge Group’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

Ally Bridge Group’s Portfolio DICE Stock Details DICE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-207,290
Closed -$3.22M – 50
2022
Q2 		$3.22M Buy
+207,290
New +$3.57M 2.93% 16

Other funds holding DICE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Ally Bridge Group's DICE Position: Q3 2022 in Review

Ally Bridge Group sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q3 2022, closing a stake of 207,290 shares — an estimated $3.22M sold.

Ally Bridge Group first reported a position in DICE in Q2 2022 and held it in 1 quarter. The position peaked at $3.22M in Q2 2022. 79 funds tracked by Wall St. Rank hold DICE as of Q3 2022.

  • Ally Bridge Group reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Ally Bridge Group sold 207,290 DICE Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $3.22M.
  • Ally Bridge Group first reported a position in DICE Therapeutics, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • Ally Bridge Group's DICE Therapeutics, Inc. Common Stock position peaked at $3.22M in Q2 2022.
  • 79 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Ally Bridge Group's 13F filing for Q3 2022, filed 14 Nov 2022.